PHAT News and Press, Phathom Pharmaceuticals Inc. From 05/25/21

FLORHAM PARK, N.J., May 25, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that members of the management team wi...

Novavax cut to neutral at JP Morgan; manufacturing issues citedNovavax (NVAX) topped Street estimates with its Q1 2021 financials, but a delayed timeline outlined for its COVID-19 vaccine candidate hurt the stock yesterday leading to a ~14.4% slump.Today, J.P. Morgan has downgraded ...

Phathom Pharmaceuticals (PHAT): Q1 GAAP EPS of -$0.96 beats by $0.24.Cash and cash equivalents were $238M.Press Release For further details see: Phathom Pharmaceuticals EPS beats by $0.24

Positive Phase 3 trial of vonoprazan in Helicobacter pylori ( H. pylori ) infection; New Drug Applications (NDAs) targeted for the fourth quarter of 2021 U.S. Food and Drug Administration (FDA) grants additional qualified infectious disease product (QIDP) designations to vonopraza...

FLORHAM PARK, N.J., May 06, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that members of the management team wi...

Phathom Pharmaceuticals (PHAT) has announced that its pivotal Phase 3 clinical trial for the eradication of H. pylori infection with vonoprazan-based regimens has reached the primary endpoints and met all secondary endpoints.The trial named PHALCON-HP was designed to evaluate vonoprazan + amo...

Phathom Pharmaceuticals (PHAT) announces that both vonoprazan-based regimens in its pivotal Phase 3 clinical trial for the eradication of H. pylori infection successfully met their main and secondary goals.The trial studied vonoprazan in combination with amoxicillin a...

Both vonoprazan-based treatment regimens demonstrated superior eradication rates vs. a standard of care proton pump inhibitor (PPI)-based triple therapy New Drug Application (NDA) submissions targeted for Q4 2021 Phathom to host conference call and live webcast today, Apri...

Phantom Pharmaceuticals is developing a next-generation stomach acid reducer that would represent the first new mechanism of action in the space in 30 years. Phantom's drug, vonoprazan, has already succeeded in multiple Phase 3 trials overseas, which should bode well for its two ongoi...

FLORHAM PARK, N.J., April 06, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that members of the management team ...